Pharmaceutical company AstraZeneca will resume some of its human trials of its COVID-19 vaccine after a short break due to a patient’s illness on Sunday.
AstraZeneca officials said trials could resume in the UK after approval through the UK Medicines Health Regulatory Authority, the Financial Times reported Saturday.
The Anglo-Swedish company did not comment on the condition of the unhealthy patient that caused his trials to stop. AstraZeneca and Oxford’s statements also did not imply whether testing in other countries such as the United States, where dozens of sites are being conducted, would allow vaccine trials to resume.
The only volunteer to get sick was one of the other 18,000 people involved in AstraZeneca’s COVID-19 “AZD1222” vaccine trials.
Although more than 1,000 patients in the trial experienced minor side effects such as chills and muscle pain, the volunteer who had the trials suspend the trials suffered a imaginable “serious adverse reaction”.
The participant in the UK reportedly had neurological symptoms indicating transverse myelitis, a rare inflammatory disorder of the spine.
An update on the participant’s condition in poor health or another diagnosis not included in AstraZeneca’s announcement to resume testing in the UK.
The AstraZeneca vaccine is being developed in collaboration with the University of Oxford and is one of nine international coronavirus vaccines that have or are about to start testing a large number of volunteers.
The company said it expects to have a COVID-19 vaccine until the end of the year. AstraZeneca is also in the U. S. Operation Warp Speed program to drive the implementation of a coronavirus vaccine. They earned $1. 2 billion in investment and pledged to supply. non-profit testing.
He and his content are provided “as is”.